PCI-32765 (Ibrutinib)

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Janssen-Cilag Farmaceutica Ltda.

Conditions

B-cell Chronic Lymphocytic LeukemiaLymphoma

Phase 2

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

CompletedNCT01779791

Janssen Research & Development, LLCLymphoma

Start: 2013-04-17End: 2016-05-18Updated: 2017-07-18

Phase 3

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

CompletedNCT01974440

Janssen Research & Development, LLCLymphoma

Start: 2014-01-31End: 2023-06-21Updated: 2025-05-25

Unknown Phase

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Janssen-Cilag Farmaceutica Ltda.B-cell Chronic Lymphocytic Leukemia

Updated: 2017-03-20

Related Papers

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Blood Advances2023-09-1821 citations

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

Cancer Medicine2021-11-176 citations

Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial

Blood2018-11-29

Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 <scp>DAWN</scp> study

Hematological Oncology2017-06-01

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Blood2016-12-029 citations

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Blood2016-12-024 citations

A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.

Journal of Clinical Oncology2015-05-205 citations

A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.

Journal of Clinical Oncology2014-05-208 citations